©The Author(s) 2020.
World J Hepatol. Dec 27, 2020; 12(12): 1326-1340
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1326
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1326
Table 3 Subclinical proximal tubulopathy prevalence at month 24 in the entecavir, naive and tenofovir disoproxil groups
| Global (n = 138); n (%); (95%CI) | ETV (n = 28); n (%); (95%CI) | Naive (n = 84); n (%); (95%CI) | TDF (n = 26); n (%); (95%CI) | P value; ETV vs naive | P value; TDF vs naive | ||
| Missing values | 45 | 9 | 22 | 14 | |||
| SPT prevalence at M24; (n = 93) | 29 (31.2%); (22.0-41.6) | 4 (21.1%); (6.1-45.6) | 19 (30.7%); (19.6-43.7) | 6 (50.00%); (21.1-78.9) | 0.421 | 0.322 | |
- Citation: Brayette A, Essig M, Carrier P, Debette-Gratien M, Labrunie A, Alain S, Maynard M, Ganne-Carrié N, Nguyen-Khac E, Pinet P, De Ledinghen V, Renou C, Mathurin P, Vanlemmens C, Di Martino V, Gervais A, Foucher J, Isabelle FH, Vergniol J, Hourmand-Ollivier I, Cohen D, Duval X, Poynard T, Bardou M, Abergel A, Dao MT, Thévenot T, Hiriart JB, Canva V, Lassailly G, Aurières C, Boyer N, Thabut D, Bernard PH, Schnee M, Larrey D, Hanslik B, Hommel S, Jacques J, Loustaud-Ratti V. Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus. World J Hepatol 2020; 12(12): 1326-1340
- URL: https://www.wjgnet.com/1948-5182/full/v12/i12/1326.htm
- DOI: https://dx.doi.org/10.4254/wjh.v12.i12.1326